Therapeutic targeting of the pituitary tumor microenvironment
Authors:
- 8 August 2023
- journal article
- review article
- Published by Elsevier in Pharmacology & Therapeutics
- Vol. 250, 108506
Abstract
No abstract availableKeywords
This publication has 87 references indexed in Scilit:
- Over-expression of vascular endothelial growth factor in pituitary adenomas is associated with extrasellar growth and recurrencePituitary, 2012
- Predictive Value of Intratumoral Microvascular Density in Patients with Advanced Non-small Cell Lung Cancer Receiving Chemotherapy Plus BevacizumabJournal of Thoracic Oncology, 2012
- Dopamine stabilizes tumor blood vessels by up-regulating angiopoietin 1 expression in pericytes and Krüppel-like factor-2 expression in tumor endothelial cellsProceedings of the National Academy of Sciences, 2011
- Anti-VEGF therapy in pituitary carcinomaPituitary, 2011
- Interleukin-8 production from human somatotroph adenoma cells is stimulated by interleukin-1β and inhibited by growth hormone releasing hormone and somatostatinGrowth Hormone & IGF Research, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Complementary Actions of Inhibitors of Angiopoietin-2 and VEGF on Tumor Angiogenesis and GrowthCancer Research, 2010
- Tumor Infiltrating Lymphocytes But Not Serum Pituitary Antibodies Are Associated with Poor Clinical Outcome after Surgery in Patients with Pituitary AdenomaThe Journal of Clinical Endocrinology & Metabolism, 2010
- Pasireotide, a multiple somatostatin receptor subtypes ligand, reduces cell viability in non-functioning pituitary adenomas by inhibiting vascular endothelial growth factor secretionEndocrine-Related Cancer, 2007
- Vasculature in nontumorous hypophyses, pituitary adenomas, and carcinomas: A quantitative morphologic studyEndocrine Pathology, 1995